Developability considerations for bispecific and multispecific antibodies
Bispecific antibodies (bsAb) and multispecific antibodies (msAb) encompass a diverse variety of formats that can concurrently bind multiple epitopes, unlocking mechanisms to address previously difficult-to-treat or incurable diseases. Early assessment of candidate developability enables demotion of...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2394229 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576522687348736 |
|---|---|
| author | Alaa Amash Gesa Volkers Patrick Farber Daniel Griffin K. Shawn Davison Allison Goodman Raffi Tonikian Aaron Yamniuk Bryan Barnhart Tim Jacobs |
| author_facet | Alaa Amash Gesa Volkers Patrick Farber Daniel Griffin K. Shawn Davison Allison Goodman Raffi Tonikian Aaron Yamniuk Bryan Barnhart Tim Jacobs |
| author_sort | Alaa Amash |
| collection | DOAJ |
| description | Bispecific antibodies (bsAb) and multispecific antibodies (msAb) encompass a diverse variety of formats that can concurrently bind multiple epitopes, unlocking mechanisms to address previously difficult-to-treat or incurable diseases. Early assessment of candidate developability enables demotion of antibodies with low potential and promotion of the most promising candidates for further development. Protein-based therapies have a stringent set of developability requirements in order to be competitive (e.g. high-concentration formulation, and long half-life) and their assessment requires a robust toolkit of methods, few of which are validated for interrogating bsAbs/msAbs. Important considerations when assessing the developability of bsAbs/msAbs include their molecular format, likelihood for immunogenicity, specificity, stability, and potential for high-volume production. Here, we summarize the critical aspects of developability assessment, and provide guidance on how to develop a comprehensive plan tailored to a given bsAb/msAb. |
| format | Article |
| id | doaj-art-020fa653c746460f9979c68b5e356aea |
| institution | Kabale University |
| issn | 1942-0862 1942-0870 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | mAbs |
| spelling | doaj-art-020fa653c746460f9979c68b5e356aea2025-01-31T04:19:38ZengTaylor & Francis GroupmAbs1942-08621942-08702024-12-0116110.1080/19420862.2024.2394229Developability considerations for bispecific and multispecific antibodiesAlaa Amash0Gesa Volkers1Patrick Farber2Daniel Griffin3K. Shawn Davison4Allison Goodman5Raffi Tonikian6Aaron Yamniuk7Bryan Barnhart8Tim Jacobs9AbCellera Biologics Inc, Vancouver, BC, CanadaAbCellera Biologics Inc, Vancouver, BC, CanadaAbCellera Biologics Inc, Vancouver, BC, CanadaAbCellera Biologics Inc, Vancouver, BC, CanadaAbCellera Biologics Inc, Vancouver, BC, CanadaAbCellera Biologics Inc, Vancouver, BC, CanadaAbCellera Biologics Inc, Vancouver, BC, CanadaAbCellera Biologics Inc, Vancouver, BC, CanadaAbCellera Biologics Inc, Vancouver, BC, CanadaAbCellera Biologics Inc, Vancouver, BC, CanadaBispecific antibodies (bsAb) and multispecific antibodies (msAb) encompass a diverse variety of formats that can concurrently bind multiple epitopes, unlocking mechanisms to address previously difficult-to-treat or incurable diseases. Early assessment of candidate developability enables demotion of antibodies with low potential and promotion of the most promising candidates for further development. Protein-based therapies have a stringent set of developability requirements in order to be competitive (e.g. high-concentration formulation, and long half-life) and their assessment requires a robust toolkit of methods, few of which are validated for interrogating bsAbs/msAbs. Important considerations when assessing the developability of bsAbs/msAbs include their molecular format, likelihood for immunogenicity, specificity, stability, and potential for high-volume production. Here, we summarize the critical aspects of developability assessment, and provide guidance on how to develop a comprehensive plan tailored to a given bsAb/msAb.https://www.tandfonline.com/doi/10.1080/19420862.2024.2394229Antibodybispecificdevelopabilityformatimmunogenicitymanufacturability |
| spellingShingle | Alaa Amash Gesa Volkers Patrick Farber Daniel Griffin K. Shawn Davison Allison Goodman Raffi Tonikian Aaron Yamniuk Bryan Barnhart Tim Jacobs Developability considerations for bispecific and multispecific antibodies mAbs Antibody bispecific developability format immunogenicity manufacturability |
| title | Developability considerations for bispecific and multispecific antibodies |
| title_full | Developability considerations for bispecific and multispecific antibodies |
| title_fullStr | Developability considerations for bispecific and multispecific antibodies |
| title_full_unstemmed | Developability considerations for bispecific and multispecific antibodies |
| title_short | Developability considerations for bispecific and multispecific antibodies |
| title_sort | developability considerations for bispecific and multispecific antibodies |
| topic | Antibody bispecific developability format immunogenicity manufacturability |
| url | https://www.tandfonline.com/doi/10.1080/19420862.2024.2394229 |
| work_keys_str_mv | AT alaaamash developabilityconsiderationsforbispecificandmultispecificantibodies AT gesavolkers developabilityconsiderationsforbispecificandmultispecificantibodies AT patrickfarber developabilityconsiderationsforbispecificandmultispecificantibodies AT danielgriffin developabilityconsiderationsforbispecificandmultispecificantibodies AT kshawndavison developabilityconsiderationsforbispecificandmultispecificantibodies AT allisongoodman developabilityconsiderationsforbispecificandmultispecificantibodies AT raffitonikian developabilityconsiderationsforbispecificandmultispecificantibodies AT aaronyamniuk developabilityconsiderationsforbispecificandmultispecificantibodies AT bryanbarnhart developabilityconsiderationsforbispecificandmultispecificantibodies AT timjacobs developabilityconsiderationsforbispecificandmultispecificantibodies |